Skip to content
x.com· @ · X·· 2026-04-23Score60

pembrolizumab

Reading

MRD / ctDNA / DTP: from detection to treatment decisions

Nivolumab, pembrolizumab and durvalumab sit in this direction not as new drugs, but because perioperative IO trials wrote ctDNA into the stratification.

Body

🎉 Exciting #AACR26 highlights!

Featured: NEOPRISM-CRC Trial - Dr. Jiang (@uclcancer) presented NeXT Personal® results in high-risk stage II-III dMMR/MSI-H colorectal cancer with neoadjuvant pembrolizumab.

✅ 100% of super molecular responders achieved pCR.
✅ 100% of poor responders did NOT achieve pCR.
✅ 100% NPV & specificity for disease relapse, post-surgery.

Study identified 3 distinct patient response groups to neoadjuvant treatment. 🎯

Other key highlights:

💪 10K patient real-world data: median LOD of 1.92 PPM.

💪 NEW Real-Time Variant Tracker™ feature for resistance monitoring.

💪 DARWIN 2: NeXT Personal risk stratified patients with NSCLC receiving immunotherapy.

Full details: https://t.co/IoHnOpviqk.

(Not affiliated with or endorsed by AACR)

#PrecisionOncology #MRD #ctDNA #ClinicalTrials #CancerResearch #TherapyDevelopment #ColorectalCancer #NSCLC #LungCancer #ImmunoTherapy #NeoadjuvantTherapy

Heat 21 · 13 likes · 0 replies · 8 reposts

Conference abstracts
CT140matched by 药名 ramucirumab
Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray

Read the abstract →
CT238NCT02706353matched by 药名 sotigalimab
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study

Salah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, Emre Arslan, Reham Abdel-Wahab, Sung-Nam Cho, Xiaodong Yang, Daniel H Johnson, Rodabe N Amaria, Isabella C Glitza, Patrick Hwu, Hussein A Tawbi, Jared K Burks, Michael A Davies, Kunal Rai, Suhendan Ekmekcioglu, Adi Diab

Read the abstract →

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org